Lucira Health to Present at the Inaugural Gilmartin Group Emerging Growth Company Showcase

EMERYVILLE, Calif., Aug. 23, 2022 (GLOBE NEWSWIRE) — Lucira Health, Inc. (“Lucira Health” or “Lucira”), a medical technology company focused on the development and commercialization of transformative and innovative infectious disease test kits, today announced that the company will participate in the Gilmartin Group Emerging Growth Company Showcase on August 31st, 2022.

Lucira’s management is scheduled to present virtually at the Inaugural Gilmartin Group Emerging Growth Company Showcase on Wednesday, August 31st, 2022, at 4:30 pm ET. A live and archived webcast of the event can be accessed through the Events and Presentations page of the Lucira website.

Those parties interested in registering for the Gilmartin Group Emerging Growth Company Showcase may do so by following this link.

About Lucira Health
Lucira is a medical technology company focused on the development and commercialization of innovative infectious disease tests to make lab-quality diagnostics more accessible. Lucira designed its test platform to provide accurate, reliable, PCR-quality test results anywhere and at any time. Beyond its already commercialized COVID-19 and COVID-19 & Flu Tests, Lucira is working on new diagnostic tests for respiratory infections and other categories including women’s health and sexually transmitted infections (STIs). For more information, visit www.lucirahealth.com.

Investor Contact
Greg Chodaczek
Investorrelations@lucirahealth.com
332-895-3230

Staff

Recent Posts

Syngene launches platform for rapid, enhanced protein production

The new proprietary cell line development platform combines a robust cell line, transposon technology with…

4 hours ago

Stanford Blood Donor Center Chooses the HemoFlow 500 and HemoVue Cloud Service to Streamline Its Whole Blood Collection Operations

GRASS VALLEY, CA / ACCESSWIRE / June 4, 2024 / Applied Science, the worldwide leader…

7 hours ago

KORU Medical Systems Announces a New Feasibility Study with a Commercialized Oncology Biologic

MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading…

10 hours ago

KORU Medical Systems Announces a New Feasibility Study with a Commercialized Oncology Biologic

MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading…

10 hours ago

AffableBPM names Greg Chavers as new Chief Revenue & Sales Officer to drive innovation in healthcare automation

SEATTLE, June 4, 2024 /PRNewswire/ -- AffableBPM, a leader in AI-powered business process automation for…

10 hours ago